Abstract
Over the past decades, there have been great advancements in the antithrombotic management of patients undergoing percutaneous interventions, but most of the available evidence derives from studies conducted in the setting of cardiac interventions. Antithrombotic treatment regimens used in patients undergoing percutaneous cardiac interventions, in particular coronary, are frequently extrapolated to patients undergoing noncardiac interventions. However, the differences in risk profile of the population treated and the types of interventions performed may translate into differences is the safety and efficacy associated with antithrombotic therapy. Noncardiac percutaneous interventions are commonly performed in patients at high bleeding risk, which may indeed impact outcomes, hence underscoring the importance of risk stratification to guide clinical decision-making processes. In this review, we appraise the available evidence on antithrombotic therapy in high-bleeding-risk patients undergoing noncardiac percutaneous interventions.
| Original language | English |
|---|---|
| Pages (from-to) | 2325-2336 |
| Number of pages | 12 |
| Journal | JACC: Cardiovascular Interventions |
| Volume | 17 |
| Issue number | 20 |
| DOIs | |
| Publication status | Published - 28 Oct 2024 |
| Externally published | Yes |
Keywords
- anticoagulant
- antiplatelet
- antithrombotic therapy
- bleeding
- high bleeding risk
- percutaneous interventions
Fingerprint
Dive into the research topics of 'Antithrombotic Therapy in High Bleeding Risk, Part II: Noncardiac Percutaneous Interventions'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver